程序性死亡受体1(PD-1)及其配体已被证明在恶性肿瘤细胞免疫逃逸中发挥重要作用。去年,美国药品和食品管理局(FDA)批准的治疗非小细胞肺癌的抗PD-1抑制剂上市,最近又批准了抗PD-L1阻滞剂治疗转移性泌尿系统上皮细胞癌。然而,免疫系统对良性肿瘤包括脉管异常的作用则关注很少。该文旨在评估PD-1和PD-L1在2种良性血管异常: Programmed death receptor 1 (PD-1) and its ligands have been shown to play an important role in the immune escape of malignant cells. Last year, the United States Drug and Food Administration (FDA) approved the listing of anti-PD-1 inhibitors for non-small cell lung cancer and recently approved anti-PD-L1 blockers for metastatic urothelial cell carcinoma. However, the immune system pays little attention to the role of benign tumors, including vascular abnormalities. The aim of this paper is to evaluate the effects of PD-1 and PD-L1 on 2 types of benign vascular abnormalities: